Evotec's Boardroom Exit Compounds a Brutal Quarter of Guidance Cuts and Restructuring Charges
Published on 08/25/2026 at 03:22 | Redaktion boerse-global.de
The turbulence at Evotec shows no sign of abating. Just days after the Frankfurt-based drug discovery specialist confirmed its sharply reduced full-year outlook, the company has been dealt another blow: supervisory board member Camilla Macapili Languille has resigned her mandate effective August 7, triggering an immediate search for a successor.
The departure lands at a delicate moment for the company, which is already wrestling with a deteriorating operational picture. When Evotec published its final second-quarter and first-half figures last Thursday, the numbers confirmed what investors had feared since the mid-July profit warning — the year is shaping up far worse than initially anticipated.
Half-Year Results Paint a Grim Picture
The financial damage is substantial. Group revenue for the first six months came in at €300.1 million, with the second quarter contributing €143.5 million. More concerning, however, is the breakdown: the Discovery & Preclinical Development segment saw revenues slide 15.2 percent to €228.1 million, while Just-Evotec Biologics also recorded a decline to €72.3 million.
The bottom line tells an even more sobering story. Evotec posted an adjusted EBITDA loss of €42.7 million for the half-year, a figure that was compounded by hefty one-off charges. Restructuring costs tied to the "Horizon" program reached €98.9 million, while an additional €42.3 million impairment added further pressure to the income statement.
A Dramatically Lower Ceiling for 2026
Management has been forced to reset expectations in a major way. Full-year revenue is now projected to land between €570 million and €610 million — a far cry from the €700 million to €780 million originally promised. The adjusted EBITDA picture is equally stark: instead of the previous range between breakeven and a €40 million profit, the company now anticipates a loss of €70 million to €105 million.
Should investors sell immediately? Or is it worth buying Evotec?
Evotec attributes the shortfall to delayed milestone payments and partnerships that closed later than scheduled. But the decision to also review its medium-term financial targets suggests management no longer views these issues as purely transitory. For investors, that signals persistently limited visibility on future earnings.
Analyst Divergence Widens
The Street has responded with mixed signals. RBC Capital Markets reaffirmed its "Outperform" rating with a €10 price target following Thursday's final Q2 numbers — a call that stands in sharp contrast to the stock's current trajectory. HC Wainwright, meanwhile, took a more cautious approach, cutting its third-quarter EPS estimate to a loss of $0.14 from a previously expected $0.04 deficit on August 14, while maintaining a buy rating and a $4.00 target.
The shares closed Monday at €3.30, hovering just above the 52-week low of €3.19 and roughly 57 percent below the year's peak of €7.75. The stock has shed about 4.7 percent since the Odyssey Therapeutics collaboration and the board resignation became known, and it remains down approximately 39 percent year-to-date. With the RSI at 33, the technical picture suggests oversold conditions — though that alone offers little comfort to holders seeking a reversal.
Strategic Work Continues Amid the Storm
Despite the financial strain, Evotec has pressed ahead with its partnership agenda. The company recently unveiled an AI-powered research collaboration with Odyssey Therapeutics focused on autoimmune and inflammatory diseases, alongside a preclinical development agreement with Niagen Bioscience for project NB4168.
On the financing front, Evotec secured additional headroom earlier this year through a subordinated, unsecured convertible bond issued in May with an initial conversion price of €6.5313. No share issuance from that instrument has been reported in the half-year results — the conversion price currently sits well above the prevailing share price, which trades just 3.8 percent above its 52-week trough.
Whether the bulls or the bears ultimately prove correct may hinge on how credible the promised review of medium-term targets turns out to be — and whether those delayed partner payments are merely postponed or lost altogether.
Ad
Evotec Stock: New Analysis - 25 August
Fresh Evotec information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
